Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 543 Squamous Cell Carcinoma of Head and Neck 280 Head and Neck Neoplasms 257 Lung Neoplasms 240 Uterine Cervical Neoplasms 180 Stomach Neoplasms 172 Esophageal Neoplasms 161 Nasopharyngeal Carcinoma 127 Urinary Bladder Neoplasms 117 Neoplasms 115 Esophageal Squamous Cell Carcinoma 115 Small Cell Lung Carcinoma 105 Ovarian Neoplasms 92 Breast Neoplasms 92 Neoplasm Metastasis 89 Cholangiocarcinoma 76 Carcinoma, Squamous Cell 76 Pancreatic Neoplasms 72 Biliary Tract Neoplasms 71 Oropharyngeal Neoplasms 57 Mesothelioma, Malignant 57 Carcinoma 55 Adenocarcinoma Of Esophagus 52 Recurrence 48 Parkinson Disease 4, Autosomal Dominant Lewy Body 47 Carcinoma, Ovarian Epithelial 46 Nasopharyngeal Neoplasms 41 Lymphoma 41 Adenocarcinoma of Lung 41 Gallbladder Neoplasms 39

Interventions

Nivolumab 5 Ipilimumab 3 relatlimab 1 daratumumab 1 Fluorouracil 1 Cisplatin 1 BMS-986115 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Various Advanced Cancer × Cisplatin × Clear all

NCT03143153 2026-02-17

CheckMate 648

Bristol-Myers Squibb

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡